Sakar Healthcare Share Price Today | Stock Price & Sakar Healthcare Share Screener
As of October 5, 2026, the live Sakar Healthcare share price (NSE: SAKAR) is ₹1,006.80, down 6.34% from the previous close, with shares trading between ₹985.00 and ₹1,094.00 in today's trading session, and a 52-week range of ₹353.00–₹1,188.40. Check Sakar Healthcare yearly highs lows for the annual price range and momentum. Use the Sakar Healthcare stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Sakar Healthcare opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹75 and net income of ₹10, with EBITDA of ₹23, an operating margin of 29.0% and a profit margin of 13.3%.
Sakar Healthcare Share Price Chart
Track the current stock price of Sakar Healthcare with an interactive chart. Analyse SAKAR share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Sakar Healthcare stock quote in one place.
The quote of ₹1,006.80 sits between the 52-week low of ₹353.00 and the 52-week high of ₹1,188.40, and the latest session moved -6.34% from the previous close.
Sakar Healthcare Company Profile - Fundamental Screener
Screen Sakar Healthcare company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SAKAR shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE732S01012.
Company Details
Classification
Identifiers and Leadership
Sakar Healthcare Balance Sheet Screener
Screen SAKAR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹481, up from ₹415 in 2025.
Latest statistics put total assets at ₹481 and shareholder funds at ₹325, with a leverage ratio of 0.26.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Assets |
|||||||
| Total Assets | 481 | 415 | 389 | 336 | 268 | 178 | 115 |
| Current Assets | 141 | 89 | 72 | 56 | 50 | 34 | 22 |
| Fixed Assets | 327 | 309 | 314 | 267 | 205 | 69 | 66 |
Liabilities |
|||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 47 | 67 | 67 | 109 | 94 | 46 | 20 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||
| Total Equity | 325 | 286 | 262 | 173 | 128 | 99 | 81 |
| Share Capital | 22 | 22 | 22 | 19 | 17 | 16 | 15 |
| Reserves & Surplus | 302 | 261 | 236 | 154 | 110 | 83 | 66 |
Sakar Healthcare Income Statement Screener - Profit & Revenue Analysis
Screen Sakar Healthcare income statement and profit fundamentals. Analyze SAKAR quarterly results. Sakar Healthcare reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹75 and net profit was ₹10, equal to earnings per unit of ₹4.62, at an operating margin of 29%.
In that period expenses were ₹52, interest cost ₹2 and tax ₹4. The next period listed, 2026-Mar, shows revenue of ₹71 and net profit of ₹11.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 75 | 71 | 71 | 59 | 53 | 50 | 44 | 43 | 42 | 44 | 38 | 35 | 41 | 43 | 35 |
| Expenses | 52 | 45 | 52 | 46 | 40 | 35 | 32 | 31 | 31 | 32 | 28 | 25 | 30 | 33 | 25 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 23 | 26 | 19 | 13 | 13 | 16 | 12 | 12 | 11 | 12 | 9 | 10 | 11 | 10 | 11 |
| Operating Profit % | 29.00% | 37.00% | 26.00% | 20.00% | 24.00% | 31.00% | 27.00% | 27.00% | 26.00% | 25.00% | 24.00% | 27.00% | 23.00% | 19.00% | 26.00% |
| Depreciation | 7 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | 5 | 4 | 4 |
| Interest | 2 | 2 | 2 | 2 | 2 | 4 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 15 | 18 | 11 | 5 | 5 | 6 | 6 | 5 | 5 | 5 | 3 | 4 | 4 | 4 | 5 |
| Tax | 4 | 7 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 1 | 1 | 0 | 1 |
| Net Profit | 10 | 11 | 10 | 5 | 5 | 6 | 5 | 5 | 2 | 3 | 2 | 4 | 3 | 4 | 4 |
| EPS | 4.62 | 4.96 | 4.59 | 2.03 | 2.11 | 2.66 | 2.08 | 2.17 | 1.10 | 1.46 | 0.98 | 1.68 | 1.46 | 2.04 | 2.16 |
Sakar Healthcare Cash Flow Screener - Liquidity Fundamentals
Screen SAKAR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹49.
Over the same period, investing activities used ₹28 and financing activities used ₹21.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | |||||||
| Operating Activities | 49 | 34 | 25 | 33 | 36 | 15 | 19 |
| Investing Activities | -28 | -31 | -52 | -74 | -90 | -47 | -22 |
Financing and Net Cash | |||||||
| Financing Activities | -21 | -4 | 27 | 41 | 55 | 32 | 4 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sakar Healthcare Shareholding Pattern Screener
See Sakar Healthcare shareholding pattern with promoter, FII, and DII holdings. Check Sakar Healthcare promoter holding and ownership changes for SAKAR on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 52.52%, foreign institutions 12.14%, domestic institutions 11.37% and the public 19.96%, spread across 14,734 shareholders.
The shareholder count was 14,734 in 2026-Jun, compared with 9,580 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 52.52% | 52.86% | 52.86% | 52.86% | 52.86% | 53.58% | 53.58% | 53.15% |
Institutional Investors | ||||||||
| FII Holding | 12.14% | 12.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 11.37% | 11.32% | 11.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 19.96% | 18.11% | 16.59% | 16.01% | 15.86% | 15.93% | 15.75% | 16.88% |
| Other Holding | 4.02% | 4.76% | 19.20% | 31.13% | 31.28% | 30.48% | 30.67% | 29.97% |
| Shareholder Count | 14,734 | 9,580 | 7,069 | 7,565 | 8,115 | 8,608 | 8,598 | 7,867 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Sakar Healthcare. Sakar Healthcare dividend yield can be compared with peers and other stocks in the market.
Sakar Healthcare Stock Index Membership - Nifty & Sensex
See which indices include Sakar Healthcare stock. Check SAKAR index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Sakar Healthcare Market Events Screener - Corporate Actions
Get Sakar Healthcare corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Sakar Healthcare stock events that may affect SAKAR share price, along with derivatives, futures and options activity and sector gainers.
9 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated July 24, 2026, with a record date of July 24, 2026.
It is followed by Quarterly Result Announcement dated May 12, 2026 and Quarterly Result Announcement dated February 5, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-07-24 | 2026-07-24 | Quarterly Result Announcement | NA | -5.71% |
| 2026-05-12 | 2026-05-12 | Quarterly Result Announcement | NA | -15.89% |
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | 5.67% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | 8.00% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 15.50% |
| 2025-02-08 | 2025-02-08 | Quarterly Result Announcement | NA | 0.83% |
| 2024-10-22 | 2024-10-22 | Quarterly Result Announcement | NA | -0.03% |
| 2024-09-21 | 2024-09-21 | Annual General Meeting | NA | -2.20% |
| 2023-12-20 | 2023-12-20 | Extraordinary General Meeting | NA | -5.45% |
Sakar Healthcare Competitors Screener - Peer Stocks Comparison
Screen SAKAR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 435,863 | 36.83 | 61,674 | 12.69% | 11,565 | 38.95 |
| Divis Laboratories | 246,660 | 86.00 | 11,067 | 13.95% | 2,568 | 53.27 |
| Torrent Pharmaceuticals | 182,577 | 86.72 | 13,886 | 20.34% | 2,138 | 42.82 |
| Zydus Life Science | 115,910 | 25.96 | 27,658 | 17.64% | 5,026 | 51.33 |
| Cipla | 108,738 | 33.29 | 29,045 | 2.24% | 3,870 | 35.23 |
| Laurus Labs | 106,982 | 98.39 | 6,868 | 22.01% | 890 | 58.13 |
| Mankind Pharma | 103,418 | 50.84 | 14,636 | 14.85% | 1,938 | 59.40 |
| Dr Reddys Laboratories | 102,916 | 32.77 | 35,059 | 3.90% | 4,158 | 62.37 |
| Aurobindo Pharma | 96,203 | 26.41 | 34,145 | 5.56% | 3,503 | 49.32 |
| Lupin | 92,839 | 16.97 | 29,039 | 26.75% | 5,356 | 31.32 |
Sakar Healthcare Company Announcements - News & Reports Screener
Screen SAKAR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 4, 2026.
The next most recent announcements are dated September 28, 2026 and September 28, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-04 | Trading Window | - |
| 2026-09-28 | Shareholders meeting | - |
| 2026-09-28 | Shareholders meeting | - |
| 2026-09-28 | Appointment | - |
| 2026-09-14 | Analysts/Institutional Investor Meet/Con. Call Updates | - |
| 2026-09-14 | Analysts/Institutional Investor Meet/Con. Call Updates | - |
| 2026-09-01 | General Updates | - |
| 2026-08-29 | Copy of Newspaper Publication | - |
| 2026-08-27 | Shareholders meeting | - |
| 2026-08-03 | Analysts/Institutional Investor Meet/Con. Call Updates | - |
| 2026-08-01 | Copy of Newspaper Publication | - |
| 2026-07-29 | Analysts/Institutional Investor Meet/Con. Call Updates | - |
| 2026-07-28 | Investor Presentation | - |
| 2026-07-24 | Outcome of Board Meeting | - |
| 2026-07-24 | Press Release | - |
| 2026-07-24 | Analysts/Institutional Investor Meet/Con. Call Updates | - |
| 2026-07-20 | General Updates | - |
| 2026-07-09 | Disclosure under SEBI Takeover Regulations | - |
| 2026-07-08 | General Updates | - |
| 2026-06-26 | Trading Window | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,006.80, within a 52-week range of ₹353.00 to ₹1,188.40. The P/E ratio is 69.16 and the P/B ratio is 7.69, with earnings per unit of ₹13.70. Market capitalisation stands at ₹2,432.03 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE. Key statistics were last updated on October 6, 2026. This page covers 7 balance sheet periods, 15 income statement periods, 7 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.